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Th   e liver is the largest metabolically active organ and is 
important in the modiﬁ   cation and detoxiﬁ  cation  of 
external agents, but is also susceptible to damage from 
these substances [1] and their metabolic intermediates. 
Liver toxicity and cardiotoxicity are the most cited 
reasons for both market withdrawal and failure during 
late-stage clinical testing of drugs [2,3]. Current animal 
models, as well as in vitro liver platforms, are poor 
predictors of human liver toxicities, with success rates as 
low as 40% [4,5]. Th   e pharmaceutical industry is therefore 
in need of better tools for predicting these toxicities in 
early stages of development in order to reduce dangerous 
clinical outcomes and drug development costs. Th  us in 
2011 the National Institutes of Health, through the 
National Center for Advancing Translational Science, the 
US Food and Drug Administration, the Environmental 
Protection Agency and the Defense Advanced Research 
Projects Agency, announced a collaboration to develop 
microphysiological systems that model major organs of 
the human body. Key requirements for these models are: 
to facilitate the assessment of biomarkers, bioavailability, 
eﬃ     cacy, and toxicity of therapeutic agents prior to 
clinical trials; and to predict the safety, eﬃ   cacy,  and 
pharmacokinetics of drug/vaccine candidates prior to 
their ﬁ  rst human use.
As participants in the National Center for Advancing 
Translational Science program, our laboratories at the 
University of Pittsburgh and at Massachusetts General 
Hospital are collaboratively developing a three-dimen-
sional microﬂ  uidic human liver acinus with integrated 
ﬂ  uorescent biosensors to improve prediction of human 
liver response to xenobiotic insults (Figure 1). Fluores-
cence-based protein biosensors can detect altered levels 
of speciﬁ  c analytes and changes of subcellular protein 
localization with spatiotemporal resolution in response 
to drugs or external stimuli [6,7]. Th   e platform comprises 
four vital cell types of the liver (hepatocytes, endothelial, 
stellate and Kupﬀ  er cells) arranged layer by layer with 
Abstract
Although the process of drug development requires 
effi   cacy and toxicity testing in animals prior to 
human testing, animal models have limited ability to 
accurately predict human responses to xenobiotics 
and other insults. Societal pressures are also focusing 
on reduction of and, ultimately, replacement of 
animal testing. However, a variety of in vitro models, 
explored over the last decade, have not been powerful 
enough to replace animal models. New initiatives 
sponsored by several US federal agencies seek to 
address this problem by funding the development 
of physiologically relevant human organ models on 
microscopic chips. The eventual goal is to simulate 
a human-on-a-chip, by interconnecting the organ 
models, thereby replacing animal testing in drug 
discovery and development. As part of this initiative, 
we aim to build a three-dimensional human liver 
chip that mimics the acinus, the smallest functional 
unit of the liver, including its oxygen gradient. Our 
liver-on-a-chip platform will deliver a microfl  uidic 
three-dimensional co-culture environment with stable 
synthetic and enzymatic function for at least 4 weeks. 
Sentinel cells that contain fl  uorescent biosensors will 
be integrated into the chip to provide multiplexed, 
real-time readouts of key liver functions and pathology. 
We are also developing a database to manage 
experimental data and harness external information to 
interpret the multimodal data and create a predictive 
platform.
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dimensional microﬂ   uidic environment mimicking a 
hepatic cord. A subset of hepatocytes and nonparen  chy-
mal cells (NPC) integrated into the device are biosensor 
sentinel cells, expressing ﬂ  uorescence-based biosensors 
of key cellular functions in order to provide quantitative, 
real-time reports of cell health and molecular modes of 
action [8]. Th   is approach seeks to extend the predictive 
relationship between hepatotoxicity triggers (mitochon-
drial damage, activation of Kupﬀ  er cell, oxidative stress) 
and the ﬁ  nal manifestation of drug-induced liver injury 
(DILI) to long-term and real-time dynamics [9]. Since 
DILI can manifest as both acute and chronic eﬀ  ects, our 
liver platform is being developed to function for at least 
4 weeks; a signiﬁ  cant technical challenge considering the 
rapid de-diﬀ  erentiation usually observed for primary cell 
cultures. Another key component of our approach is the 
develop  ment of a database application that will access 
informa  tion from major drugs, drug targets, bioassays 
and pathway databases. Related chemical, bioactivity, 
pre  clinical and clinical data will be used for aiding the 
interpretation of microphysiology readouts and develop-
ment of computational models to predict the safety and 
toxicity of new compounds. Th  e database design aim is 
ultimately to integrate the other microphysiological 
organ systems to complete a human-on-a-chip database.
Capturing precise liver p  hysiology in vitro
Th  e liver comprises two major cell populations: paren-
chymal cells (hepatocytes) and NPCs, including endo-
thelial cells, stellate cells and Kupﬀ  er cells among others. 
Th   e inspiration for our platform is the liver sinusoid and 
the acinus, the smallest metabolic functional unit of the 
liver. Th  ere are four crucial aspects of liver physiology 
captured in our design: a three-dimensional architecture; 
multiple cell types; physiological microcirculation; and 
zonation.
A model that aims to recapitulate the intricate auto-
crine and paracrine interaction between diﬀ  erent cells of 
the liver should include the major parenchymal cell and 
NPC types as well as a three-dimensional microcellular 
environment mimicking the acinus–sinusoid [10]. Th  e 
three-dimensional architecture shaped by the collagen 
sandwich in tissue culture plates was an important 
development in the long-term stable metabolic and 
synthetic function of hepatocytes [11]. Co-cultures of 
Figure 1. Liver acinus module with microchip. (A) The liver acinus module with a microchip, including a diagram of four liver cell types and 
sentinel biosensor cells layered in the device. (B) High content analysis of microchip device and quantitation. (C) Graphic depiction of data from 
device and external sources supplied to database.
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further, as well as modify the response to drugs as 
compared with monocultures of hepatocytes [12-14]. 
Kupﬀ  er cells, for example, are known to contribute to 
DILI during acetaminophen toxicity [15]. Th  ese co-
cultures can also stabilize cells after unavoidable injury 
[13]. Recent results show that both human and rat 
hepatocytes are stable for over 3 months in a co-culture 
with their respective NPC fraction, with improved res-
ponse to drug induction of clinically relevant cytochrome 
P450 enzymes [12], highlighting the importance of a co-
culture over standard monocultures. Further, arranging 
the co-cultures into sinusoid-like structures improves 
albumin secretion and cytochrome P450 activity for over 
2  months [16]. Th  e latter is important as evidence 
suggests reactive metabolites are often the cause of 
unanticipated DILI. Evidence further conﬁ  rms that three-
dimensional co-cultures, either on a scaﬀ   old or as a 
spheroid, improve both the longevity and toxicological 
response [12,17,18].
Microcirculatory ﬂ  ow can also modulate the response of 
hepatocytes [19] and of endothelial cells [20], and can form 
the oxygen zonation that is important for site-directed 
injury and the transport of nutrients and waste 
metabolites. However, when exposing cells to ﬂ  ow, it is 
important to emulate physiologically relevant conditions 
including appropriate shear stress, drug residence times, 
and chemical gradients. Th  e  microﬂ  uidic approaches allow 
for such emulation as well as providing high-throughput 
test beds for pharmacokinetic and toxicity studies.
Modes of action to predict human hepatoxicity and 
approach
Th   e exact molecular basis for many instances of DILI is 
unknown. A major goal of our project is to identify real-
time functional responses associated with hepatotoxicity 
using sentinel cells [21]. We are developing the sentinel 
cells of various cell types to respond to several molecular 
signatures that are associated with hepatotoxicity [22]. 
Based on our previous experience with biosensors, we 
are developing hepatocyte sentinel cells to report meta-
bolic alterations due to apoptosis, oxidative stress, 
phospholipidosis, and intrahepatic cholestasis caused by 
inhibition of bile eﬄ   ux transport, among others [7,23,24]. 
Kupﬀ  er cell activation in response to the injury trigger 
will be used to measure immune dysfunction that occurs 
as a result of reaction to a drug, a drug metabolite, or a 
protein altered by a reactive drug metabolite [25]. Stellate 
cells will have biosensors to monitor proliferation that 
results from ﬁ   brosis associated with cholestasis or 
mitochondrial failure [26]. Cells placed in the chip are 
also conﬁ  rmed for intermediary metabolism.
Our vision is to use a microﬂ  uidic device where the 
hepatic and sentinel cells are arranged in parallel 
micro  grooves in a sinusoid-like architecture 
(Figure  2A,B,C) [27]. Th  e cells at the inlet of these 
channels consume oxygen, which generates an oxygen 
gradient along the ﬂ  ow direction of the device. Previous 
work on microﬂ  uidic liver(s)-on-a-chip used feeder cells 
to stabilize cultures, but lacked long-term functional data 
and had no incorporation of NPCs in a three-dimensional 
architecture [28-30]. Although bioreactors include longer 
culture times and multiple cell types, they are not suited 
for microﬂ  uidic format [31]. Our strategy is to seed the 
hepatocytes and add the NPCs sequentially. Th   e cells will 
be proportioned in appropriate physiological ratios of 70 
to 80% hepatocytes, 15 to 20% endothelial cells, 5 to 10% 
stellate cells and 5 to 10% Kupﬀ  er cells.
Our initial prototype for cell culture and parameter 
optimization is a cell culture chamber 10  mm long, 
1.5 mm wide, and 100 μm tall, fabricated out of poly-
dimethyl  siloxane [32]. In preliminary work, approxi-
mately 12,000 seeded hepato  cytes demonstrated stable 
hepatocyte function  ality for 10 days of culture under a 
static (no-ﬂ   ow) condition, showing excellent viability 
(Figure 2D,E). Although the device incorporates human 
cells, prelimi  nary device optimization was carried out 
using primary rat liver cells. Similarly, polydimethyl-
siloxane used in prototypes will be replaced with more 
robust materials. Th  e functional data are supported by 
periodic cell viability assays as well as visualization of the 
intracellular albumin (Figure 2F).
A novel concept in our vision is to integrate multiple 
live, stable, and nondestructive cellular reporters of test 
drug eﬀ  ects to enable the early prediction of DILI using 
high content analysis. A subset of primary human liver 
cells is eﬃ     ciently transformed into sentinel cells by 
lentiviral gene delivery of ﬂ  uorescent protein biosensors. 
Long-term high content analysis can be carried out 
within the microﬂ   uidic device without the need for 
oﬄ   ine analysis [33] (Figure 1). Th   e sentinel cell data are 
quantiﬁ  able to assess the toxicity, metabolic functions, 
and key modes of action responses to drugs over time. 
Initial studies of sentinel cell primary human hepatocytes 
report increased reactive oxygen species (Figure  2FG) 
and mitochondrial impairment (Figure 2H,I) in response 
to known hepatotoxins versus a vehicle control. Import-
antly, these responses are time and concentration depen-
dent, reproducible, quantitative and collected by non-
destructive techniques. Sentinel cell data will be 
integrated with biochemical and metabolic measure-
ments to monitor drug clearance and cytochrome P450 
induction, glucose consumption, and urea and albumin 
secretions. Th   e sentinel cell concept will advance the ﬁ  eld 
because it enables the study of primary cell heterotypic 
interactions due to drug response and enables the study 
of dynamic cellular response from within a functional 
liver model.
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models, is the organization and analysis of large and 
complex datasets to predict human organ eﬃ   cacy and 
safety [21]. We are constructing a database application to 
collect, manage, and analyze data from the real-time 
readouts, biochemical assays, and mass spectrometry. 
Beyond data management, the database will incorporate 
access to clinically relevant hepatotoxic and non  hepato-
toxic drug exposure results, and biochemical and meta-
bolic activities in order to establish the concordance of 
the liver chip data with in vivo eﬀ  ects. To achieve this 
goal, a selection of reference compounds with available 
clinical data will be proﬁ  led in the liver chip, and the 
resulting dataset will be used to construct predictive 
models of human hepatotoxicity.
Conclusions and future directions
We are particularly interested in using the liver acinus 
module to investigate DILI, which leads to pathologies 
such as ﬁ   brotic scarring, fatty liver disease, reduced 
metabolic detoxiﬁ  cation, and even liver failure [1]. An 
important cause of DILI is human genetic variability that 
can lead to altered liver metabolism and response to 
drugs. Our long-term goal is to seed the liver microchip 
with induced pluripotent stem cell-derived adult-like 
hepatocytes to characterize and predict hepatotoxicity 
Figure 2. Preliminary results. (A) Diagram of fl  ow conditions for hepatocytes in collagen gel in the microfl  uidic device. PDMS, 
polydimethylsiloxane. (B) Microfl  uidic channels 50 μm wide, 10 mm long, and 100 μm tall with grooves to represent a liver sinusoid. (C) Phase 
image of primary hepatocytes in a microgrooved channel [27]. (D), (E) Live primary rat hepatocytes stained for live (celcein)/dead (ethidium 
homodimer-1) cells at days 3 and 9. (F) Fixed primary rat hepatocytes stained for intracellular albumin (anti-rat albumin antibody; Abcam, 
Cambridge, MA, USA). (G), (H) Primary human hepatocyte sentinel cells expressing reactive oxygen species (ROS) biosensor treated with 
dimethylsulfoxide (DMSO; control) or 100 μmol menadione for approximately 4 hours. (I), (J) Primary human hepatocyte sentinel cells expressing 
mitochondrial function biosensor treated with DMSO (control) or 100 μmol menadione, approximately 16 hours after addition of treatments.
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acinus module is modular and reconﬁ  gurable, we plan to 
combine it with other organ platforms to begin assessing 
multiorgan toxicities. Key elimination organs that have 
direct interaction with the liver, such as the gut and 
kidney, are of particular importance because they can 
provide robust pharmacokinetic modeling. Th   is plan ﬁ  ts 
our goals of: generating a microscale platform technology 
to support human physiological organ systems; maintain-
ing the liver module at high, stable levels of function for 
at least 4  weeks; and utilizing real-time high content 
measure  ments and a reference database to improve the 
prediction of human liver toxicity. Finally, sentinel 
biosensor cells can be developed for other organs and the 
general design of our database application is adaptable 
for other organ models.
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